What if a cancer-causing mutation were less like a ticking time bomb and more like an actor waiting for the right opportunity? Team SPECIFICANCER’s brand new paper gives us an insight.
The new paper from SPECIFICANCER, published in @Nature, reveals that it’s not just the mutation that matters — it’s where in the liver that mutation appears. Understanding which cells can turn cancerous — and why — helps us better predict risk and develop smarter, more targeted treatments.
Congratulations to the #CancerGrandChallenges SPECIFICANCER team (co-funded by @TheMarkFdn). This work was led by Owen Sansom and Future Leader Alex Raven.
👉 Read more from Alex: https://t.co/L4dpfswgRn
#CancerResearch